

Amendments to the Specification:

Please amend the paragraph [0021], at page 3, lines 8-12, as follows

Sustained release is suitably obtained by use of a non disintegrating matrix tablet formulation, for example by incorporating Eudragit RS (ammonio methacrylic acid copolymer Type B) into the tablet. Alternative non disintegrating matrix tablet formulations are provided by incorporating methacrylates (a methacrylic acid copolymer), cellulose acetates, hydroxypropyl methylcellulose phthalate, in particular Eudragit L (methacrylic acid copolymer Type C) and RL (methacrylic acid copolymer Type A), Carbopol 971P, HPMCP-HP-55S into the tablet.

Please amend the paragraph [0022], at page 3, lines 13-15, as follows

Sustained release is further obtained by use of a disintegrating matrix tablet formulation, for example by incorporating methacrylates (a methacrylic acid copolymer), methylcellulose, in particular Eudragit L[[;]] (methacrylic acid copolymer Type C) or Methocel K4M (hydroxypropyl methylcellulose having a nominal viscosity of 4000) into the tablet.